Pure Global AI
NCT06347705Recruiting

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Phase II Study Evaluating the Effects of Single Site Intratumoral Injections of Anti-CD40 Agonist Antibody (2141-V11) Given as Monotherapy Prior to Radical Prostatectomy to Men With Intermediate Risk Disease and in Combination With Androgen Deprivation Therapy for Those With High Risk Localized and Low Volume Metastatic Disease
Memorial Sloan Kettering Cancer CenterPhase 2ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Prostate Cancer
Drug/Device/Intervention
2141-V11 Antibody
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Rockville Centre, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 28, 2024
End date
Mar 28, 2029
Enrollment
99 participants
Primary outcome

Number of participants with a complete response or minimal residual disease.

Summary

The purpose of this study is to see whether combining 2141-V11 with various standard
 treatments is an effective treatment approach for prostate cancer. 2141-V11 works by
 activating the immune system to find and kill cancer cells. Researchers will look at whether
 this treatment approach is able to completely get rid of cancer in participants, and they
 will check for the presence of minimal residual disease (MRD) in participants. MRD is a small
 number of cancer cells that can be detected in the body after treatment.

ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06347705
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06347705 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 99 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.